案例 Products
产品名称

Multiple Sclerosis

发布时间 2018-03-04
点击次数 50
  • 基本参数
  • 部件材质
  • 应用概述
  • 相关下载

         Multiple Sclerosis

         Introduction


         Multiple sclerosis (MS), also known as disseminated sclerosis, is an autoimmune condition with demyelination of central nerves often resulting in physical and cognitive disabilities in many patients. It has a prevalence of 2 to 150 per 100,000 in the population,  usually occurring in young adults and females.                                 

Multiple Sclerosis Multiple SclerosisSeveral disease-modifying treatments are currently available in different countries, including: Avonex and Rebif (interferon beta- 1a), Betaseron or Betaferon (interferon beta-1b), Copaxone (polypeptide Glatiramer acetate), Mitoxantrone (immunosuppressant) and Natalizumab (humanized monoclonal antibody).

 For several decades, rodent experimental autoimmune encephalomyelitis (EAE) has been broadly used as an important pharmacology model in new drug discovery and evaluation for MS. Mechanistic investigations on the immunopathogenesis of the demyelinating process, in different EAE models, have greatly elucidated the responsible mechanisms for autoimmune-caused neurological tissue damage and concepts of different therapeutic strategies.

         

         PharmaLegacy Models and Research Tools


                  

      EAE Models               SJL mice               C57BL/6 mice              Lewis rats

Antigen 

Specificity

                   PLP 139-151

                     MOG 35-55                        MBP

Disease Onset 

and Recovery

          Day 12-14,  no recovery               Day 12-14,  no recoveryDay 10-12,  recover within  6-8 days
Disease TypeRelapsing-remittingChronic progressionMonophase progression

Similarities 

to HumanDisease

Relapsing-remitting  disease course with demyelination and axonal damageChronic-progressive disease course with demyelination and axonal damage

T cell inflammation and weak antibody response



        Utility

Two-episode disease.

Ideal for studying the effects of immunotherapeutic agents and various treatment regimens.

Variable disease incidence and course with cytotoxic demyelination.

Ideal for studying T cell, macrophage mediated demyelination, axonal injury in demyelinated plaques and demyelinating anti-MOG autoantibody response.

High reproducibility. The acute onset and spontaneous recovery

resemble the exacerbation and remission seen in MS.

Primary

Endpoints

         EAE disease score, incidence, mortality, mean maximum disease score, group mean score, EAE onset and duration, body weight

Additional

Endpoints

         Histopathology,  immunohistochemistry,  hematology,  cytokines  /  chemokine  analysis, T  cell proliferation, permeability of BBB


         Related Capabilities



         *Disease transfer model: T-cell adoptive transfer in mice

         *Assays for antigen-specific T-cell responses

         *Flow cytometry analysis of cell functions including intracellular staining of cytokines

         *Western blotting detection of signal transduction


Case Study - PLP Induced EAE Model



                  

         Effects of Cyclosporin (CsA) on PLP induced chronic relapse EAE in SJL mice:

Mice were subcutaneously immunized with PLP peptide emulsion. The symptom of EAE development (Red) represents the disease progression of human relapsing-remitting MS. Daily oral administration of the reference drug, CsA (a widely documented immunosuppressant for EAE) (Blue), demonstrates its effectiveness in stopping disease onset. The section of spinal cord showed a significant inflammatory cells infiltrations in the White matter (left) when compared to the CsA (right) treated mice.


         Multiple SclerosisMultiple SclerosisMultiple Sclerosis

                                                                                                         Vehicle                                                   CsA 

     

         PharmaLegacy’s fully validated EAE models are backed by many years’ experience in MS research and animal modeling and produce a very reproducible disease induction and results. These models have been providing clients with the options of various treatment strategies / regimens at different stages of relapsing-remitting progression, closely simulating the therapeutic options for patients.






Products / 相关产品
2018 - 03 - 01
Asthma is a chronic inflammatory disorder of the airways in which many infiltrating cells (such as mast cells, eosinophils, T lymphocytes, macrophages, neutrophils, and epithelial cells) and cellular ...
2018 - 03 - 02
Delayed Type Hypersensitivity     Introduction     Delayed type hypersensitivity (DTH), also known as cell mediated immune memory response or type IV ...
2018 - 02 - 02
Inflammatory Bowel DiseaseIntroductionInflammatory bowel disease (IBD) is a chronic relapsing and remitting inflammatory condition of the gastrointestinal tract that is usually manifest as 1 of 2 dist...
Copyright ©2013 - 2018 
澎立生物医药技术(上海)有限公司
X
1

QQ设置

3

SKYPE 设置

4

阿里旺旺设置

5

电话号码管理

  • +86-21-6100-2270
6

二维码管理

等待加载动态数据...

等待加载动态数据...

回到顶部
展开